4.7 Review

Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women JACC State-of-the-Art Review

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 75, 期 20, 页码 2602-2618

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.03.060

关键词

adverse pregnancy outcomes; aspirin; atrial fibrillation; cardiovascular disease; gestational diabetes

资金

  1. Novartis
  2. Esperion
  3. Amgen
  4. National Institutes of Health
  5. NIHF
  6. NIH/NHLBI [HL146158]
  7. NIH/NCATS (University of Florida Clinical and Translational Science) [UL1TR001427]
  8. Gatorade Trust through the University of Florida Department of Medicine
  9. McJunkin Family Foundation
  10. U.S. Department of Defense [PR161603]

向作者/读者索取更多资源

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for women in the United States and worldwide. There has been no American College of Cardiology (ACC)/American Heart Association guideline update specifically for the prevention of CVD in women since 2011. Since then, the body of sex-specific data has grown, in addition to updated hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines. The ACC CVD in Women Committee undertook a review of the recent guidelines and major studies to summarize recommendations pertinent to women. In this update, the authors address special topics, particularly the risk factors and treatments that have led to some controversies and confusion. Specifically, sex-related risk factors, hypertension, diabetes, hyperlipidemia, anticoagulation for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocial issues are (C) 2020 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据